Bacteriophage RNA polymerases: catalysts for mRNA vaccines and therapeutics

Dec 6, 2024Frontiers in molecular biosciences

Virus enzymes that help make mRNA vaccines and treatments

AI simplified

Abstract

Key mechanistic insights on bacteriophage-derived RNA polymerases could enhance mRNA manufacturing efficiency.

  • The efficiency of mRNA manufacturing is crucial for the success of mRNA-based products.
  • Application of the (QbD) framework may improve the critical quality attributes of mRNA drug substances.
  • Critical process parameters and critical material attributes are associated with key performance indicators in mRNA production.
  • The structure-function relationship of T7 RNA polymerase and its engineered mutants could lead to lower immunogenicity in mRNA therapeutics.
  • Alternatives to standard RNA polymerases are discussed in the context of large-scale in vitro transcription processes.

AI simplified

Full Text

What this is

  • Bacteriophage-derived RNA polymerases (RNAPs) are crucial for synthesizing mRNA, particularly for vaccines.
  • This review discusses the evolution of RNAPs, focusing on T7 RNAP's role in mRNA manufacturing.
  • It explores the application of the () framework to enhance mRNA production efficiency.
  • The review also examines alternatives to T7 RNAP and the economic implications of improving mRNA manufacturing.

Essence

  • Bacteriophage-derived RNA polymerases, especially T7 RNAP, are central to mRNA synthesis for vaccines. Implementing () principles can optimize production processes, reduce impurities, and enhance economic viability.

Key takeaways

  • T7 RNAP is the gold standard for mRNA synthesis, enabling large-scale production during the COVID-19 pandemic. Its efficiency and specificity make it ideal for industrial applications.
  • () principles can significantly improve mRNA manufacturing by optimizing critical process parameters (CPPs) and critical material attributes (CMAs), leading to better quality attributes (CQAs) of the final product.
  • Exploration of mutant RNAPs and alternatives derived from other bacteriophages may reduce product-related impurities and enhance the efficiency of mRNA synthesis.

Caveats

  • The review primarily focuses on T7 RNAP, which, while extensively characterized, may not fully represent the capabilities of less-studied alternatives. Regulatory hurdles could impede the adoption of these alternatives in industrial settings.
  • Despite the potential benefits of mutant RNAPs, extensive characterization is required to ensure their reliability and effectiveness in large-scale manufacturing.

Definitions

  • Quality by Design (QbD): A systematic approach to pharmaceutical development that emphasizes designing quality into products and processes from the outset.

AI simplified

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free